# Age-Associated Genetic Variations in Breast Cancer: Somatic Mutations and Co-Mutations

**Authors:** Busra Ekinci, Seda Orenay-Boyacioglu, Ibrahim Halil Erdogdu, Olcay Boyacioglu, Merve Cirak-Balta, Nesibe Kahraman-Cetin, Ibrahim Meteoglu

PMC · DOI: 10.3390/biomedicines14030510 · Biomedicines · 2026-02-25

## TL;DR

This study finds that while overall genetic mutations in breast cancer don't differ much with age, certain mutations like PIK3CA are more common in older patients, suggesting personalized treatment could benefit from age-specific genetic profiling.

## Contribution

The study provides the first comprehensive molecular characterization of geriatric breast cancer patients in Türkiye, highlighting age-specific genetic alterations.

## Key findings

- PIK3CA mutations were significantly more frequent in geriatric breast cancer patients compared to non-geriatric patients.
- ATR mutations were more common in HER2-enriched breast cancer subtypes.
- TP53 mutations correlated with higher Ki-67 proliferation indices in breast cancer patients.

## Abstract

Background/Objectives: Breast cancer (BCa) is a heterogeneous disease with molecular and genetic characteristics that significantly influence prognosis and treatment strategies. Age-related differences in tumor biology may impact therapeutic decisions; however, data on somatic mutation profiles in geriatric patients are limited. Methods: This retrospective study included 371 BCa patients (53 geriatric ≥ 65 years, 318 non-geriatric) whose clinicopathological and next-generation sequencing (NGS) data were analyzed. Immunohistochemical markers and molecular subtypes were assessed according to ASCO/CAP guidelines. Mutational profiles were obtained using the QIAseq Human BCa Panel (93 genes). Results: Among all patients, 1669 somatic mutations were detected, and 93.3% of patients harbored at least one mutation. Mutation prevalence was similar between geriatric (96.2%) and non-geriatric (92.8%) groups (p = 0.526), indicating that age did not significantly affect overall mutational burden. The most frequently mutated genes were ATR, TP53, PIK3CA, PTEN, RAD50, BLM, NF1, AR, BRCA2, and KMT2C. Notably, PIK3CA mutations were significantly more frequent in geriatric patients (28.3% vs. 23.2%, p = 0.0418). TP53 mutations correlated with higher Ki-67 proliferation indices (p = 0.035), while ATR mutations were more common in HER2-enriched subtypes (p = 0.002). Conclusions: Our findings indicate that while the overall somatic mutational load in BCa does not differ significantly with age, specific molecular alterations—particularly the enrichment of PIK3CA mutations in elderly patients—underscore the importance of integrating genomic profiling into personalized treatment planning. This study represents the first comprehensive molecular characterization of geriatric BCa patients in Türkiye, providing valuable insights for age-specific genetic profiling, treatment optimization, and future multicenter translational studies.

## Linked entities

- **Genes:** ATR (ATR checkpoint kinase) [NCBI Gene 545], TP53 (tumor protein p53) [NCBI Gene 7157], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], PTEN (phosphatase and tensin homolog) [NCBI Gene 5728], RAD50 (RAD50 double strand break repair protein) [NCBI Gene 10111], BLM (BLM RecQ like helicase) [NCBI Gene 641], NF1 (neurofibromin 1) [NCBI Gene 4763], AR (androgen receptor) [NCBI Gene 367], BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675], KMT2C (lysine methyltransferase 2C) [NCBI Gene 58508]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, KMT2C (lysine methyltransferase 2C) [NCBI Gene 58508] {aka HALR, KLEFS2, MLL3}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, RAD50 (RAD50 double strand break repair protein) [NCBI Gene 10111] {aka NBSLD, RAD502, hRad50}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, BLM (BLM RecQ like helicase) [NCBI Gene 641] {aka BS, MGRISCE1, RECQ2, RECQL2, RECQL3}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}
- **Diseases:** BCa (MESH:D001943), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023819/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13023819/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023819/full.md

---
Source: https://tomesphere.com/paper/PMC13023819